Irritable bowel syndrome and probiotics: From rationale to clinical use

Current Opinion in Gastroenterology

Volumn 21, Issue 6, 2005, Pages 697-701

  Verdu, Elena F ^a   Collins, Stephen M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Functional bowel disorders; Gut dysfunction; Irritable bowel syndrome; Probiotics

Indexed keywords

DSM 12246; LP 299; NCC 2461; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; BIFIDOBACTERIUM LONGUM INFANTIS; CAMPYLOBACTER; CLINICAL TRIAL; COLITIS; CYTOKINE RELEASE; DRUG MECHANISM; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; MEDLINE; NONHUMAN; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SACCHAROMYCES BOULARDII; SALMONELLA; SHIGELLA; SYMPTOM;

ANIMALS; CLINICAL TRIALS; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 27644557307     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000182861.11669.4d     Document Type: Review

References (41)

1. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318:565-566.
2. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-811.
3. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin-1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52:523-526.
4. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122:1778-1783.
5. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702. This was the first study to demonstrate a correlation between activated mast cells and symptom severity in IBS patients.
6. Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24:405-411.
7. King TS, Elia M, Hunter OH. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352:1187-1189.
8. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109:40-52.
9. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98:1187-1192.
10. Naliboff BD, Munkata J, Fullerton S, et al. Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997; 41:505-512.
11. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20:1253-1269.
12. Silverman DH, Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112:64-72.
13. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacilli and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-551. This clinical trial demonstrated an imbalance in systemic proinflammatory and counterinflammatory cytokines that can be corrected by specific probiotic therapy.
14. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-782.
15. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53:1096-1101.
16. James C, Thabane M, Borgaonkar M, Marshall J. Post-infectious irritable bowel syndrome is transient following a foodborne outbreak of acute gastroenteritis attributed to a viral pathogen. Gastroenterology 2004; 126(suppl 2): A-53.
17. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123:1972-1979.
18. Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52:91-93.
19. Van der Veek, de Kroon Y, van der Berg M, et al. Tumor necrosis factor alpha and interleukin 10 gene polymorphism in irritable bowel syndrome. Gastroenterology 2004; 126(suppl 2):A-52.
20. Huang JS, Bousvaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002; 47:2625-2634.
21. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002; 50:54-59.
22. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52:988-997.
23. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116:1107-1114.
24. Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11:372-378.
25. Verdu EF, Bercik P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127:82. This was the first study to demonstrate the differential effects of probiotic strains on neuromuscular function in a model of PI-IBS.
26. Lamine F, Eutamene H, Fioramonti J, et al. Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats. Scand J Gastroenterol 2004; 39:1250-1258.
27. Rosenfeldt V, Benfeldt E, Valerius NH, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004; 145:612-616.
28. Jain PK, McNaught CE, Anderson ADG, et al. Influence of symbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomized controlled trial. Clin Nutr 2004; 23:467-475.
29. McNaught CE, Woodcock NP, Anderson AD, Macfie J. A prospective randomized trial of probiotics in critically ill patients. Clin Nutr 2005; 24: 211-219.
30. Verdú EF, Bercik P, Bergonzelli G, et al. Lactobacillus paracasei normalizes post-infective dysmotility in vivo and induces a sustained attenuation of inflammatory mediators. Gastroenterology 2004; 126(suppl 2):A170.
31. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352:1187-1189.
32. Balsari A, Ceccarelli A, Dubini F, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5:185-194.
33. Kamm K, Hoppe S, Breves G, et al. Effects of the probiotic yeast Saccharomyces boulardii on the neurochemistry of myenteric neurons in pig jejunum. Neurogastroenterol Motil 2004; 16:53-60.
34. Verdu EF, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic-induced visceral hypersensivity in mice. Gut 2005 [Epub ahead of print].
35. Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome: a controlled clinical investigation from general practice. Scand J Prim Health Care 1989; 7:23-26.
36. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95:1231-1238.
37. Sen S, Mullan MM, Parker TJ, et al. Effect of lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47:2615-2620.
38. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38:S104-S106.
39. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147.
40. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome: a randomized double-blind placebo-controlled cross-over study. Dig Liver Dis 2000; 32:294-301.
41. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904.